For what it is worth, the E3 ligand for PROTAC in our study was lenalidomide, and in the study by Luke M Simpson et al. [42], PROTAC with lenalidomide as the E3 ligand was able to degrade ER proteins more efficiently, so based on the cellular location of these candidate target proteins and their correlation with tumor development, we finally selected BI-1 as a potential target. Here, TMBIM6 is linked to neoplasm.